Present situation in the treatment of invasive fungal infection

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 2, 2008, Pages

  de Pauw, Ben E ^a   Picazo, Juan J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Antifungal agents; Empirical antifungal therapy; Invasive fungal infection; Pre emptive therapy; Prophylaxis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BETA LACTAM ANTIBIOTIC; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ABDOMINAL ABSCESS; ANTIFUNGAL RESISTANCE; ANTIGEN DETECTION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDEMIA; CANDIDIASIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ERROR; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEVER; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOLOGY; HUMAN; IMMUNE DEFICIENCY; LUNG LAVAGE; MUCORMYCOSIS; MYCOSIS; OROPHARYNX CANDIDIASIS; PERITONITIS; PRIORITY JOURNAL; RISK FACTOR; UNSPECIFIED SIDE EFFECT; ZYGOMYCETES;

ANTIFUNGAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES;

EID: 55649104952     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(08)70020-7     Document Type: Article

References (35)

1. Bow E.J., Loewen R., Cheang M.S., Shore T.B., Rubinger M., and Schachter B. Cytotoxic therapy-induced d-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 15 (1997) 2254-2261
2. Bennet J.E. Echinocandins for candidemia in adults without neutropenia. N Engl J Med 355 (2006) 1154-1159
3. Pfaller M.A., Pappas P.G., and Wingard J.R. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 43 Suppl 1 (2006) S3-14
4. Pfaller M.A., and Diekema D.J. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42 (2004) 4419-4431
5. Segal B.H., Almyroudis N.G., Battiwalla M., et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 44 (2007) 402-409
6. Cornely O.A., Maertens J., Bresnik M., et al., AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 44 (2007) 1289-1297
7. Poirier J.M., and Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 35 (1998) 461-473
8. Johnson L.B., and Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36 (2003) 630-637
9. Dannaoui E., Meletiadis J., Mouton J.W., Meis J.F., and Verweij P.E. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 51 (2003) 45-52
10. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
11. Perfect J.R., Marr K.A., Walsh T.J., et al. Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin Infect Dis 36 (2003) 1122-1131
12. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347
13. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
14. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
15. Petrovic J., Ngai A., Bradshaw S., et al. Efficacy and safety of caspofungin in solid organ transplant recipients. Transplant Proc 39 (2007) 3117-3120
16. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
17. Maertens J., Raad I., Pettrikos G., et al. Efficacy and safety of caspofungin for the treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
18. Reboli A.C., Rotstein C., Pappas P.G., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356 (2007) 2472-2482
19. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326 (1992) 845-851
20. Slavin M.A., Osborne B., Adams R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 171 (1995) 1545-1552
21. Glasmacher A., Prentice A., Gorschluter M., et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21 (2003) 4615-4626
22. Pizzo P.A., Robichaud K.J., Gill F.A., and Witebsky F.G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72 (1984) 101-107
23. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86 (1989) 668-672
24. Wingard J.R. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 39 Suppl 1 (2004) S38-S43
25. Wheat L.J. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis 8 (2006) 128-139
26. Rubin R.H. Preemptive therapy in immunocompromised hosts. N Engl J Med 324 (1991) 1057-1058
27. Caillot D., Couaillier J.F., Bernard A., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19 (2001) 253-259
28. Becker M.J., Lugtenburg E.J., Cornelissen J.J., Van Der Schee C., Hoogsteden H.C., and De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 121 (2003) 448-457
29. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at risk of invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41 (2005) 1242-1250
30. Senn L., Robinson J., Schmidt S., et al. 1,3-b-d-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 46 (2008) 878-885
31. De Pauw B.E. Between over-and undertreatment of invasive fungal disease. Clin Infect Dis 41 (2005) 1251-1253
32. Walsh T.J., Raad I., Patterson T.F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44 (2007) 2-12
33. Spellberg B.J., Filler S.G., and Edwards J.E. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 42 (2006) 244-251
34. Garey K.W., Rege M., Pai M.P., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43 (2006) 25-31
35. Marr K.A., Boeckh M., Carter R.A., Woo Kim H., and Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39 (2004) 797-802